Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment-resistant schizophrenia.

Helio Elkis1

  • 1Department and Institute of Psychiatry, University of Sao Paulo Medical School (FMUSP), São Paulo, SP, Brazil. helkis@usp.br <helkis@usp.br>

The Psychiatric Clinics of North America
|August 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Moderators of Cognitive Behavioural Therapy for Psychosis Versus Other Psychological Interventions: An Individual-Participant Data Meta-Analysis.

Focus (American Psychiatric Publishing)·2026
Same author

Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.

The American journal of psychiatry·2025
Same author

Response to the Letter to the Editor "Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia" (Jolly et al. Schizophrenia Research, 267 (2024) 32-33).

Schizophrenia research·2025
Same author

Corrigendum to "The danger of averages in the context of heterogeneity: Response to the letter to the editor of SCZ RES - role of ECT in patients with CRS - Markota et al., 2024" [Schizophr. Res. 269 (2024): 120-122].

Schizophrenia research·2024
Same author

Response to Markota et al. "Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia" SCHRES-D-24-00481.

Schizophrenia research·2024
Same author

The danger of averages in the context of heterogeneity: Response to the letter to the editor of SCZ RES- role of ECT in patients with CRS-Markota et al. 2024.

Schizophrenia research·2024
Same journal

Digital Mental Health: Progress but not Perfection.

The Psychiatric clinics of North America·2026
Same journal

Advances in Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

The Future of Digital Mental Health: A Literature Review.

The Psychiatric clinics of North America·2026
Same journal

Assessment and Treatment of Posttraumatic Stress Disorder via Digital Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Treatment of Obsessive-Compulsive Disorder via Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Digital Mental Health Treatments for Depression.

The Psychiatric clinics of North America·2026
See all related articles

This review covers the history of schizophrenia pharmacotherapy and focuses on treatment-resistant schizophrenia (TRS). It highlights clozapine as a key treatment option for patients with TRS, supported by clinical and neuroimaging data.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Neuroimaging

Background:

  • Schizophrenia pharmacotherapy has evolved significantly.
  • Treatment-resistant schizophrenia (TRS) presents a major clinical challenge.
  • Understanding correlates of TRS is crucial for effective management.

Purpose of the Study:

  • To provide a historical overview of schizophrenia pharmacologic treatment.
  • To define treatment-resistant schizophrenia (TRS).
  • To discuss treatment options for TRS, emphasizing clozapine.

Main Methods:

  • Literature review of pharmacologic treatments for schizophrenia.
  • Analysis of clinical, biological, and neuroimaging correlates of TRS.
  • Evaluation of treatment strategies for TRS.

Related Experiment Videos

Main Results:

  • Treatment-resistant schizophrenia is characterized by specific clinical and biological markers.
  • Clozapine is identified as a primary therapeutic option for TRS.
  • Neuroimaging studies offer insights into the pathophysiology of TRS.

Conclusions:

  • Effective management of TRS requires a comprehensive understanding of its characteristics.
  • Clozapine remains a cornerstone treatment for patients with treatment-resistant schizophrenia.
  • Further research into biological and neuroimaging correlates may refine TRS treatment approaches.